Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 6/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 6/20 | 0.63 |
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | APEX1 | P27695 | 1/20 | 0.58 |
| ▸ | WNT3A | P56704 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130422 | 0.88 | RAB9A (0.66) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL28524227 | 0.86 | RAB9A (0.64) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2937866 | 0.86 | RAB9A (0.64) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6070720 | 0.85 | PDE4D (0.68) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8339369 | 0.85 | LMNA (0.65) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2857382 | 0.85 | LMNA (0.53) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2201890 | 0.84 | LMNA (0.64) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8090996 | 0.84 | CYP1A2 (0.67) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15331881 | 0.83 | POLB (0.57) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8031114 | 0.83 | RAB9A (0.61) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896023-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2008-03-12 | — | — | EP | claimed |
| WO-2006138259-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-12-28 | — | — | WO | claimed |
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIV OF MARYLAND BALTIMORE (US) | 2026-05-21 | — | — | US | disclosed |
| US-12378220-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3423452-B1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIV MARYLAND (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240316017-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | LG CHEM, LTD. (KR) | 2024-09-26 | — | — | US | disclosed |
| US-20240300944-A1 | NOVEL UREA DERIVATIVE COMPOUND AS RON INHIBITOR | LG CHEM, LTD. (KR) | 2024-09-12 | — | — | US | disclosed |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-06-27 | — | — | US | disclosed |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-06-27 | — | — | US | disclosed |
| US-11993729-B2 | Chemical mechanical polishing composition | BASF SE (DE) | 2024-05-28 | — | — | US | disclosed |
| WO-2024102639-A1 | N-ARYLPYRAZOLE NOD2 AGONISTS AS PROMOTERS OF IMMUNE CHECKPOINT INHIBITOR THERAPY | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20050004176-A1 | Pyrazole-amide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-06 | — | — | US | disclosed |
| WO-2004098518-A2 | PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-18 | — | — | WO | disclosed |
| EP-0550111-B1 | 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them | SANOFI SA (FR) | 1999-04-14 | — | — | EP | disclosed |
| US-5856349-A | 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | SANOFI (FR) | 1999-01-05 | — | — | US | disclosed |
| US-5652254-A | TREATMENT OF DEGENERATIVE DISEASES, RHEUMATOID ARTHRITIS, PSORIASIS, CYSTIC FIBROSIS | SANOFI, S.A. (FR) | 1997-07-29 | — | — | US | disclosed |
| US-5563163-A | TREATMENT OF DEGENERATIVE DISEASES | STERLING WINTHROP, INC. (US) | 1996-10-08 | — | — | US | disclosed |
| US-5488062-A | 2-saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1996-01-30 | — | — | US | disclosed |
| US-5376653-A | A protease enzyme inhibitor for treating degenerative diseases , respiratory system disorders, rheumatoid arthritis and pancreatitis | STERLING WINTHROP INC. (US) | 1994-12-27 | — | — | US | disclosed |
| EP-0550111-A1 | 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them | STERLING WINTHROP INC. (US) | 1993-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378220-B2 | WNT signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | MEN1 2583/4885KMT2A 4305/4885CYP1A2 4591/4885 |
| US-20240316017-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | RET, ROS1, MST1R | MEN1 1577/4885KMT2A 2876/4885CYP1A2 4597/4885 |
| US-20240300944-A1 | NOVEL UREA DERIVATIVE COMPOUND AS RON INHIBITOR | CDKN1A, RET, UBTF | MEN1 1555/4885KMT2A 3163/4885CYP1A2 4766/4885 |
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | CTNNB1, WNT1, CTNND1 | MEN1 4746/4885KMT2A 3577/4885CYP1A2 3782/4885 |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | WNT1, CTNNB1, WNT3A | MEN1 2583/4885KMT2A 4305/4885CYP1A2 4591/4885 |
| US-20050004176-A1 | Pyrazole-amide compounds useful as kinase inhibitors | MAP3K1, MAP3K5, MAP3K7 | MEN1 3632/4885KMT2A 2826/4885CYP1A2 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.